Evidence map›Paper›PMID 39979699›Full record

ArticleDiscover oncology2025

Association of DBNDD1 with prognostic and immune biomarkers in invasive breast cancer.

Xinzhu Huang, Yiyang Wang, Junyi Wang, Yubo Jing, Elihamu Dilraba, Yongxiang Li, Chenming Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xinzhu Huang *Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Yiyang Wang *Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Junyi Wang *Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Yubo JingDepartment of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Elihamu DilrabaDepartment of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Yongxiang LiDepartment of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Chenming GuoDepartment of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China. gcm_xjmu@yeah.net.

Funding

National Natural Science Foundation of China 32260186Regional Collaborative Innovation Special Project (Science and Technology Assistance to Xinjiang Program) 2022E02136the Xinjiang Uygur Autonomous Region Youth Science and Technology Top-notch Talent Program 2022TSYCCX0029
6 · The paper itself

Abstract

backgroundDysbindin domain-containing 1 (DBNDD1) is strongly connected with the occurrence and development of malignancies, but the DBNDD1 function and mechanism in invasive breast cancer (IBC) remain poorly understood. Our objective was to ascertain the possible diagnosis and prognostic importance of DBNDD1 in IBC.

methodAn analysis was done to ascertain the connection between the DBNDD1 expression level in IBC and clinicopathological features employing the relevant databases, and to evaluate DBNDD1 in the diagnosis and prognosis of IBC. We explored possible cellular mechanisms and biological functions as well as explored DBNDD1-related interacting proteins, analyzed DBNDD1 methylation status, and investigated its correlation with immune cell infiltration. The effect of DBNDD1 on the function of breast cancer (BC) cells was studied in vitro.

resultDBNDD1 mRNA and protein levels exhibited higher expression in IBC, and were significantly correlated with a worse outcome. DBNDD1 hypomethylation status was linked to a negative prognosis. Enrichment analysis revealed that the genes exhibiting a positive correlation with DBNDD1 expression were mostly enriched in pathways linked to DNA synthesis and DNA methylation. Furthermore, the DBNDD1 expression level exhibited a substantial correlation with the immune cell infiltration in tissue. DBNDD1 overexpression emerged to enhance the BC cell's proliferation, invasion and migration as well as suppress the BC cell's apoptosis, as validated by in vitro tests.

conclusionDBNDD1 upregulation is directly linked to the tumor immune cell infiltration and the unfavorable IBC prognosis. DBNDD1 possesses the capacity to be a biomarker for diagnosing and predicting the outcome of a disease, as well as a possible target for therapeutic interventions in IBC.

Indexed as

BioinformaticsDBNDD1Immune cell infiltrationInvasive breast cancerPrognosis

Identifiers

PMID39979699
PMCPMC11842647

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.